News and Updates

From March 15–18, more than 200 passionate, motivated Breakthrough T1D Advocates from all 50 states convened in Washington, D.C., for Breakthrough T1D 2026 Government Day. Government Day remains one of Breakthrough T1D’s most impactful ways to effect change. By bringing the lived type 1 diabetes (T1D) experience directly to policymakers, we are accelerating progress toward […]

Nearly 3 years after Breakthrough T1D joined forces with Civica, a non-profit pharmaceutical company, its first insulin is now available for purchase at pharmacies across the country. Check out our story from October that highlights the years of partnership between Civica and Breakthrough T1D that made today a reality. We worked with our partners at […]

What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]

This past week, the FDA and Sanofi, the maker of Tzield, made an important announcement. Tzield, the first disease-modifying therapy approved for delaying onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D, has been accepted into the FDA Commissioner’s National Priority Voucher (CNPV) program for people with stage 3 T1D. […]

Nearly 3 years ago, Breakthrough T1D joined forces with Civica Rx, a non-profit pharmaceutical company, to manufacture and distribute low-cost insulins. Starting on January 1, 2026, the first of those insulins, insulin glargine-yfgn (a long-acting insulin interchangeable with Lantus®), will be available for purchase. 5 pens, no more than $55 – for anyone While we […]

Breakthrough T1D recently published two peer-reviewed journal articles. One detailed burdensome unmet needs in the T1D community and identified key steps we can take to meet these needs. The other used real-world data to better understand American T1D demographics and predict changes in the next decade.

Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to unlock access to manufactured islet therapies for people with T1D.

Breakthrough T1D headed to Washington D.C. where advocates held nearly 500 meetings with Members of Congress on behalf of the T1D community.

While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D.   This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D.   Here are the […]

On October 1st, the T1D community got a big win: the Centers for Medicare and Medicaid Servies (CMS) introduced a unique ICD-10 code for stage 2 type 1 diabetes (T1D). This addresses a significant gap in clinical care. Prior to this change, clinicians had limited options for coding stage 2 T1D, which resulted in inaccurate […]